Gaviscon Burning and Indigestion 24 Sachets

WARNINGS
Each 10 ml dose (1 sachet) has a sodium content of 127.25 mg (5.53 mmol). This should be taken into consideration in cases where a particularly low-salt diet is recommended, for example in some cases of congestive heart failure and renal impairment. Each 10 ml (1 sachet) dose contains 130 mg (3.25 mmol) of calcium. Care should be taken when treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones. If symptoms do not improve after seven days, the clinical picture should be reassessed. Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216), which can cause allergic reactions (including delayed). Prolonged use should be avoided. As with other anti-acid medicinal products, taking the medicinal product can mask the symptoms of other more serious pre-existing diseases. The drug should not be used in the following cases: patients with severe renal impairment / renal insufficiency; patients with hypophosphataemia. There is a possibility of reduced efficacy in patients with very low gastric acid levels. There is an increased risk of hypernatremia in children with gastroenteritis or suspected renal insufficiency. Treatment of children under the age of 12 is generally not recommended, unless prescribed.
PHARMACOTHERAPEUTIC CATEGORY
drugs for the treatment of peptic ulcer and gastroesophageal reflux disease.
STORAGE
Do not store above 30 degrees C. Do not refrigerate or freeze.
CONTRAINDICATIONS / SECONDARY EFFECT
known or suspected hypersensitivity to the active substances or to any of the excipients.
NAME
GAVISCON BURNING AND INDIGESTION
EXCIPIENTS
Carbomer 974P; methyl parahydroxybenzoate (E218); propyl parahydroxybenzoate (E216); sodium saccharin; mint flavor; sodium hydroxide; purified water.
SIDE EFFECTS
Very rarely (<1 / 10,000) patients sensitive to drug components may develop allergic manifestations such as hives or bronchospasm, anaphylactic or anaphylactoid reactions, abdominal pain, itchy rash, diarrhea, nausea and vomiting. Ingestion of large amounts of calcium carbonate can cause alkalosis, hypercalcemia, acid return, milk-alkali syndrome or constipation. These symptoms normally occur following the intake of doses higher than the recommended dose.
PREGNANCY AND BREASTFEEDING
Open-label controlled studies in 281 pregnant women have not shown any significant undesirable effects of the drug on the course of pregnancy or on the health of the fetus / newborn. Based on this and previous experience, the medicine can 'be used during pregnancy and lactation. However, in consideration of the presence of calcium carbonate, it is recommended to limit the duration of treatment as much as possible. Pre-clinical investigations on animals have shown that alginate has no negative effect on the fertility of the parental generation and offspring or on reproduction. Clinical data do not suggest that the drug may have an effect on fertility in humans.
INDICATIONS
Treatment of acid-related symptoms of gastroesophageal reflux, such as acid regurgitation, heartburn and indigestion, for example after meals or during pregnancy.
INTERACTIONS
Due to the presence of calcium carbonate which acts as an antacid, it is necessary to consider a time interval of two hours from taking the drug and the administration of other medicinal products, especially antihistamines-antiH2, tetracyclines, digoxin, fluoroquinolones, salts of iron, ketoconazole, neuroleptics, tyrosine, penicillamine, beta-blockers (atenonol, metoprolol, propanolol), glucocorticoids, chloroquine and bisphosphonates).
DOSAGE
For oral administration. Adults and children 12 years and older: 10-20 ml (1 to 2 sachets) after meals and in the evening before going to bed, up to four times a day. Children under 12 years: should only be given on medical advice. Senior citizens: it is not necessary to modify the doses for this age group.
ACTIVE PRINCIPLES
Sodium alginate 500 mg, sodium bicarbonate 213 mg and calcium carbonate 325 mg.